Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Spain
  4. Bolsas y Mercados Espanoles
  5. Oryzon Genomics S.A.
  6. News
  7. Summary
    ORY   ES0167733015

ORYZON GENOMICS S.A.

(ORY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oryzon Genomics S.A. enrolls first patient in the US in PORTICO

10/18/2021 | 08:00am EST

Oryzon Genomics, S.A. announced the enrollment of the first patient in the US in its Phase IIb clinical trial with vafidemstat, a selective inhibitor of the epigenetic target LSD1, in Borderline Personality Disorder (BPD) patients. PORTICO is a multicenter, double-blind, randomized, placebo-controlled Phase IIb trial to evaluate the efficacy and safety of vafidemstat in BPD patients. The two primary independent objectives of the trial are a reduction of aggression and agitation and an overall improvement of BPD. The study aims to include 156 patients in total, with 78 patients in each arm, and has an adaptive design with a pre-defined interim analysis to adjust the sample size in case of excessive variability around the endpoints or an unexpectedly high placebo rate. The study is already approved in Europe by the Spanish, German and Bulgarian Medicine Agencies. PORTICO builds on clinical data from the Phase IIa REIMAGINE trial, where vafidemstat reduced agitation-aggression in patients with attention deficit and hyperactivity disorder (ADHD), autism spectrum disorder (ASD) and BPD after 2 months of treatment, and from the Phase IIa REIMAGINE-AD trial, where vafidemstat reduced agitation-aggression in patients with severe and moderate Alzheimer's disease after 6 months of treatment. Vafidemstat has proven to be safe and well-tolerated across multiple clinical trials in more than 300 treated subjects, some on continuous therapy for up to 24 months. PORTICO’s scientific rationale is based on vafidemstat’ s ability to inhibit selectively LSD1 and modulate aggression and sociability, as tested in several preclinical models.


ę S&P Capital IQ 2021
All news about ORYZON GENOMICS S.A.
11/22Oryzon Genomics S.A. Appoints Saikat Nandi Has Been Appointed as Global Chief Business ..
CI
11/22ORYZON GENOMICS S A : announces new Global Chief Business Officer and expansion of US corp..
PU
11/17Oryzon Genomics, S.A. Announces Enrollment of First Patient in EVOLUTION Phase IIb Clin..
CI
11/17ORYZON GENOMICS S A : enrolls first patient in EVOLUTION, a Phase IIb clinical trial with ..
PU
11/15ORYZON GENOMICS S A : publishes paper in ACS Pharmacology & Translational Science supporti..
PU
11/09Oryzon Genomics S.A. to Present New Clinical Data and Corporate Updates At Internationa..
CI
11/09ORYZON to present new clinical data and corporate updates at international conferences ..
PU
10/28ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2021
GL
10/28ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2021
GL
10/28Oryzon Genomics S.A. Reports Earnings Results for the Third Quarter and Nine Months End..
CI
More news
Financials
Sales 2021 - - -
Net income 2021 -5,01 M -5,67 M -5,67 M
Net cash 2021 13,0 M 14,7 M 14,7 M
P/E ratio 2021 -32,8x
Yield 2021 -
Capitalization 160 M 181 M 181 M
EV / Sales 2021 -
EV / Sales 2022 64,8x
Nbr of Employees 43
Free-Float 80,3%
Chart ORYZON GENOMICS S.A.
Duration : Period :
Oryzon Genomics S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ORYZON GENOMICS S.A.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,03 €
Average target price 10,00 €
Spread / Average Target 230%
EPS Revisions
Managers and Directors
Carlos Manuel Buesa Arjol Chairman, President & Chief Executive Officer
Enric Rello Condomines Chief Operating & Financial Officer
Sonia Paloma Gutierrez Chief Clinical Operations
Jordi Xaus Chief Scientific Officer
Xavier Perpinya Ribera Head-Internal Audit & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ORYZON GENOMICS S.A.-13.43%181
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625